Get the Stockscreener App
110.22
8.05%
8.21
After Hours:
108.00
-2.22
-2.01%
Celcuity Inc stock is traded at $110.22, with a volume of 848.51K.
It is up +8.05% in the last 24 hours and up +2.64% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$102.01
Open:
$103.56
24h Volume:
848.51K
Relative Volume:
1.17
Market Cap:
$5.10B
Revenue:
-
Net Income/Loss:
$-162.72M
P/E Ratio:
-30.02
EPS:
-3.6714
Net Cash Flow:
$-144.89M
1W Performance:
-2.04%
1M Performance:
+2.64%
6M Performance:
+112.21%
1Y Performance:
+948.72%
1-Day Range:
$103.56
$110.61
1-Week Range:
$100.01
$115.08
52-Week Range:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
110.22 | 4.72B | 0 | -162.72M | -144.89M | -3.6714 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Transcript : Celcuity Inc., Q4 2025 Earnings Call, Mar 25, 2026 - marketscreener.com
Celcuity Q4 Earnings Call Highlights - Yahoo Finance
CELC: FDA priority review, strong trial data, and robust cash position set stage for 2026 launch - TradingView
Earnings call transcript: Celcuity beats Q4 2025 EPS forecast, stock rises - Investing.com
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib - ChartMill
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Beats Estimates By $0.33 EPS - MarketBeat
CELCUITY ($CELC) Releases Q4 2025 Earnings - Quiver Quantitative
Celcuity Q4 Adjusted Loss Narrows - marketscreener.com
Celcuity Inc. reports release of fourth quarter and full year 2025 financial results and provides corporate update - marketscreener.com
Celcuity Inc. Reports Release Of Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Update - TradingView
BRIEF-Celcuity Q4 Adjusted EPS USD -0.73 Vs. IBES Estimate USD -1.04 - TradingView
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Celcuity earnings up next as breast cancer drug nears approval By Investing.com - Investing.com Canada
Why Celcuity’s Hot Stock Is Suddenly Cooling - TipRanks
Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result - MSN
Aug Drivers: Is Celcuity Inc stock a smart retirement pick2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Celcuity (CELC) Projected to Post Earnings on Monday - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
Celcuity Inc.: Fundamental Analysis and Financial Ratings | 7VR | US15102K1007 - marketscreener.com
CELC Stock Price, Quote & Chart | CELCUITY INC (NASDAQ:CELC) - ChartMill
Aug Breakouts: Should I set a stop loss on Celcuity Inc2026 Sentiment & Risk Controlled Daily Plans - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After VIKTORIA-1 Data And New Analyst Buy Rating - Sahm
Celcuity (CELC) price target increased by 11.17% to 108.57 - MSN
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call - The Manila Times
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and ... - Bluefield Daily Telegraph
Why (CELC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Needham & Company LLC Reiterates Buy Rating for Celcuity (NASDAQ:CELC) - MarketBeat
HighVista Strategies LLC Purchases New Position in Celcuity, Inc. $CELC - MarketBeat
49,281 Shares in Celcuity, Inc. $CELC Purchased by Granahan Investment Management LLC - MarketBeat
Celcuity publishes Phase 3 trial results in medical journal - Investing.com Nigeria
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Celcuity prices $248.7M debt, stock offerings - MSN
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders - Yahoo Finance
90,000 Shares in Celcuity, Inc. $CELC Purchased by Boxer Capital Management LLC - MarketBeat
Apis Capital Advisors LLC Acquires New Holdings in Celcuity, Inc. $CELC - MarketBeat
The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data - simplywall.st
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference - MarketBeat
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Celcuity: Undervalued Pipeline with Differentiated Clinical Profile Supports Buy Rating - TipRanks
15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC - MarketBeat
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - simplywall.st
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com South Africa
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib demonstrates leading efficacy in breast cancer, with launch and global expansion underway - TradingView
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):